Tourmaline Bio Forms Cardiovascular Scientific Advisory Board
Tourmaline Bio is taking significant steps to enhance its cardiovascular program with the formation of a Cardiovascular Scientific Advisory Board (CV SAB). This initiative brings together leading experts in cardiovascular medicine, promising to propel the company's innovative treatment, pacibekitug, forward as it aims for potential Phase 3 clinical trial readiness.
Expertise and Strategic Guidance
The newly established CV SAB is expected to play a critical role in the strategic direction of Tourmaline's cardiovascular diseases program. As Tourmaline progresses with the TRANQUILITY Phase 2 clinical trial, which began earlier this year, the board's insights will help refine clinical development and strategy to ensure successful outcomes.
Meet the Advisory Board
The Cardiovascular Scientific Advisory Board consists of distinguished professionals who bring a wealth of knowledge and experience:
- Joshua Beckman, MD, MSc – UT Southwestern Medical Center
- Marc Bonaca, MD, MPH – University of Colorado, CPC Clinical Research
- Robin Choudhury, MA, DM, FRCP – University of Oxford
- Douglas L. Mann, MD – Washington University School of Medicine
- James Min, MD – Cleerly, Inc.
- Pradeep Natarajan, MD, MMSc – Massachusetts General Hospital
- Michael D. Shapiro, DO, MCR – Wake Forest University School of Medicine
- Michael Szarek, PhD – University of Colorado, CPC Clinical Research
Enhancing Patient Care through Innovation
Emil deGoma, MD, Senior Vice President of Medical Research at Tourmaline, expressed enthusiasm about welcoming the board, emphasizing that their varied expertise in areas such as atherosclerotic cardiovascular disease (ASCVD) and heart failure will be instrumental in advancing the pacibekitug program.
About Pacibekitug
Pacibekitug, also known as TOUR006, is a promising therapeutic candidate that represents a potential advancement in treating cardiovascular diseases. It is a long-acting, fully-human anti-IL-6 monoclonal antibody, designed to exhibit best-in-class characteristics. Tourmaline has completed six clinical trials involving around 450 participants with autoimmune disorders.
Currently, pacibekitug is in development for atherosclerotic cardiovascular disease and thyroid eye disease (TED) as its primary indications, with the potential for expansion into further diseases in the future.
The Path Ahead for Tourmaline Bio
As Tourmaline Bio continues its journey towards redefining standards of care for high-risk cardiovascular patients, the insights from the CV SAB will be pivotal. The board's guidance is set to enhance the development of pacibekitug, aiming to address urgent medical needs and improve patient outcomes.
Frequently Asked Questions
What is the newly formed Cardiovascular Scientific Advisory Board?
The Cardiovascular Scientific Advisory Board is a group of leading experts assembled by Tourmaline Bio to guide the development of their cardiovascular program.
Who are the members of the Cardiovascular Scientific Advisory Board?
The board includes distinguished professionals from institutions such as UT Southwestern, University of Colorado, and Wake Forest University, among others.
What is the goal of pacibekitug?
Pacibekitug aims to offer innovative treatment options for patients with cardiovascular diseases, specifically targeting conditions like atherosclerotic cardiovascular disease.
Why is the CV SAB important for Tourmaline Bio?
The CV SAB provides strategic guidance and expertise that will help shape the trajectory of Tourmaline's cardiovascular program as it prepares for clinical trials.
What advances have been noted in pacibekitug's development?
Pacibekitug has shown promise in several completed clinical trials and is set to advance towards Phase 3 clinical trial readiness with the support of the CV SAB.
